Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) saw unusually-strong trading volume on Tuesday . Approximately 286,494 shares were traded during trading, an increase of 28% from the previous session’s volume of 223,317 shares.The stock last traded at $5.48 and had previously closed at $5.35.

Several equities analysts have recently commented on GNCA shares. FBR & Co restated a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $17.95.

The stock’s 50-day moving average price is $5.18 and its 200 day moving average price is $4.68. The company’s market capitalization is $154.70 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/genocea-biosciences-inc-gnca-sees-strong-trading-volume-2.html

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative return on equity of 47.87% and a negative net margin of 5,121.17%. Equities research analysts forecast that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. purchased a new position in shares of Genocea Biosciences during the first quarter valued at approximately $103,000. Alpine Partners VI LLC purchased a new position in shares of Genocea Biosciences during the second quarter valued at approximately $120,000. TFS Capital LLC purchased a new position in shares of Genocea Biosciences during the second quarter valued at approximately $133,000. Dimensional Fund Advisors LP purchased a new position in shares of Genocea Biosciences during the second quarter valued at approximately $143,000. Finally, Ameriprise Financial Inc. purchased a new position in shares of Genocea Biosciences during the second quarter valued at approximately $156,000. 56.49% of the stock is owned by hedge funds and other institutional investors.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

5 Day Chart for NASDAQ:GNCA

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.